Clinical Trial Update: Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP [Phase 3]

View source ↗

Summary

An ongoing Phase 3 long-term safety and efficacy study of riliprubart in participants with chronic inflammatory demyelinating polyneuropathy (CIDP), currently e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Riliprubart

Snippet

Sponsor: Sanofi | Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | Status: ENROLLING_BY_INVITATION